December 2010, Volume 12, Issue 6, pp 614-627
Date: 16 Oct 2010
Current and Future Status of Stem Cell Therapy in Heart Failure
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
As heart transplantation and mechanical assist technology are inadequate solutions for the growing clinical epidemic of heart failure, myocardial regeneration has moved to the forefront. Multiple laboratories using a variety of cell types have demonstrated myocardial repair in different animal models. Translating these results into clinical practice through clinical trial research has thus far proved challenging. Amassing clinical evidence suggests that cell therapy is safe and offers a modest clinical benefit, but the long-term effect of such therapy as well as the overall impact on the natural progression of heart failure and, ultimately, survival are unknown. Furthermore, cost-benefit analysis of such therapy, which will likely become increasingly important as health care reform takes shape, has not been examined to any degree. Although scientific competition has driven this field with remarkable speed, it is also responsible for its fragmentation, with multiple avenues of pursuit happening in parallel. Consensus opinion is absent with respect to mechanism of action, effectiveness of cell type or delivery method, timing and dosing of cell therapy, adjunctive medication or therapies, and optimum cell type or combination of cell types. Nevertheless, in the arena of clinical medicine, ease of cell availability and cell delivery has proved paramount to cell type selection. The flourish of clinical trials investigating bone marrow–derived stem cells (BMSCs) delivered via direct intracoronary injection testifies to this opinion. The modest improvements in cardiac function demonstrated in trials to date will likely not have a significant clinical impact. We expect, however, that scientific competition will make continued contributions over the next decade that will propel the field forward, resulting in more pronounced clinical benefits in future trials. The authors further believe that the realization of true cardiac regeneration will require the use of autologous cells more capable of retention and differentiation to cardiac cell lineages. We believe that endogenous cardiac progenitor cells have superior regenerative potential to current cell types in this regard. The difficulty in accessing, isolating, and expanding these cells has resulted in less preclinical and clinical interest. Ongoing investigation will better define the capabilities of these cardiac progenitor cells.
References and Recommended Reading
Papers of particular interest, published recently, have been highlighted as:• Of importance •• Of major importance
Nelson TJ, Ge ZD, Van Orman J, et al.: Improved cardiac function in infarcted mice after treatment with pluripotent embryonic stem cells. Anat Rec A Discov Mol Cell Evol Biol 2006, 288:1216–1224.PubMed
Molcayni M, Bentz K, Maegele M, et al.: Embryonic stem cell transplantation after experimental traumatic brain injury dramatically improves neurological outcome, but may cause tumors. J Neurotrauma 2007, 4:216–225.
Rumyantsev P: Some comparative aspects of myocardial regeneration. In Muscle Regeneration. By Mauro A. New York: Raven Press; 1979:335–355.
Ghostine S, Carrion C, Souza LC, et al.: Long-term efficacy of myoblast transplantation on regional structure and function after myocardial infarction. Circulation 2002, 106(Suppl 1):I131–136.PubMed
Randomized clinical trial of adipose-derived stem cells in the treatment of pts with st-elevation myocardial infarction. Available at http://clinicaltrials.gov/ct2/show/NCT00442806?term=APOLLO&rank=6. Accessed August 2010.
A randomized clinical trial of adipose-derived stem cells in treatment of non revascularizable ischemic myocardium. Available at http://clinicaltrials.gov/ct2/show/NCT00426868?term=precise&rank=14. Accessed August 2010.
Lagasse E, Connors H, Al-Dhalimy M, et al.: Purified hematopoietic stem cells can differentiate into hepatocytes in vivo. Nat Med 2001, 6:1229–1234.CrossRef
Castro-Malaspina H, Gay RE, Resnick G, et al.: Characterization of human bone marrow fibroblast colony-forming cells (CFU-F) and their progeny. Blood 1980, 56:289–301.PubMed
Tendera M, Wojakowski W, Ruzyllo W, et al.: Intracoronary infusion of bone marrow-derived selected CD34 + CXCR4+ cells and nonselected mononuclear cells in patients with acute STEMI and reduced left ventricular ejection fraction: results of randomized, multicentre Myocardial Regeneration by Intracoronary Infusion of Selected Population of Stem Cells in Acute Myocardial Infarction (REGENT) Trial. Eur Heart J 2009, 30:1313–1321.CrossRefPubMed
Arnold R, Villa A, Gutierrex H, et al.: Absence of accelerated atherosclerotic disease progression after intracoronary infusion of bone marrowdervied mononuclear cells in patients with acute myocardial infarctio-angiographic and intravascular ultrasound-results from the terapia cellular aplcada al miocardio pilot study. Am Heart J 2010, 159:1154.e1–1154.e8.
Fischer-Rosakat U, Assmus B, Seeger FH, et al.: A pilot trial to assess potential effects of selective intracoronary bone marrow derived progenitor cell infusion in patients with nonischemic dilated cardiomyopathy: final 1-year results of the transplantation of progenitor cells and functional regeneration enhancement pilot trial in patients with nonischemic dilated cardiomyopathy. Circ Heart Fail 2009, 2:417–423.CrossRef
Lunde K, Solheim S, Aakhus S, et al.: Intracoronary injection of mononuclear bone marrow cells in acute myocardial infarction. N Engl J Med 2006, 12:1199–1209.CrossRef
Traverse JH, Henry TD, Vaughn DE, et al.: Rationale and design for TIME: a phase II, randomized, double-blin, placebo-controlled pilot trial evaluating the safety and effect of timing of administration of bone marrow mononuclear cells after acute myocardial infarction. Am Heart J 2009, 158:356–363.CrossRefPubMed
The Percutaneous Stem Cell Injection Delivery Effects on Neomyogenesis Pilot Study (The POSEIDON-Pilot Study). Available at http://clinicaltrials.gov/ct2/show/NCT01087996?term=poseidon&rank=2. Accessed August 2010.
The Transendocardial Autologous Cells (hMSC or hBMC) in Ischemic Heart Failure Trial (TAC-HFT). Available at http://clinicaltrials.gov/ct2/show/NCT00768066?term=TAC&rank=9. Accessed August 2010.
D’Alessandro DA, Kajstura J, Hosoda T, et al.: Progenitor cells from the explanted heart generate immunocompatible myocardium within the transplanted donor heart. Circ Res 2009, 5:1128–1140.CrossRef
- Current and Future Status of Stem Cell Therapy in Heart Failure
Current Treatment Options in Cardiovascular Medicine
Volume 12, Issue 6 , pp 614-627
- Cover Date
- Print ISSN
- Online ISSN
- Current Science Inc.
- Additional Links